Press Releases

Press Releases

November 11, 2021
CytomX Therapeutics to Present at Upcoming November Investor Conferences
SOUTH SAN FRANCISCO, Calif. , Nov. 11, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics , Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated therapeutics, today announced that Sean McCarthy , D.Phil ., president, chief executive officer, and chairman, will participate in virtual
Additional Formats
October 18, 2021
CytomX Therapeutics Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif. , Oct. 18, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics , Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platform, today
Additional Formats
October 4, 2021
CytomX Therapeutics Appoints Dr. Alan Ashworth to Board of Directors
SOUTH SAN FRANCISCO, Calif. , Oct. 04, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platform, today
Additional Formats
September 16, 2021
CytomX Therapeutics Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif. , Sept. 16, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics , Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platform, today
Additional Formats
August 17, 2021
CytomX Therapeutics Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif. , Aug. 17, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics , Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody® technology
Additional Formats
Displaying 1 - 10 of 30